These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 6135869

  • 1. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.
    Finne J, Leinonen M, Mäkelä PH.
    Lancet; 1983 Aug 13; 2(8346):355-7. PubMed ID: 6135869
    [Abstract] [Full Text] [Related]

  • 2. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ.
    Contrib Microbiol Immunol; 1989 Aug 13; 10():151-65. PubMed ID: 2479499
    [No Abstract] [Full Text] [Related]

  • 3. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides.
    Häyrinen J, Jennings H, Raff HV, Rougon G, Hanai N, Gerardy-Schahn R, Finne J.
    J Infect Dis; 1995 Jun 13; 171(6):1481-90. PubMed ID: 7769282
    [Abstract] [Full Text] [Related]

  • 4. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis.
    Pon RA, Lussier M, Yang QL, Jennings HJ.
    J Exp Med; 1997 Jun 02; 185(11):1929-38. PubMed ID: 9166422
    [Abstract] [Full Text] [Related]

  • 5. Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo.
    Saukkonen K, Haltia M, Frosch M, Bitter-Süerman D, Leinonen M.
    Microb Pathog; 1986 Feb 02; 1(1):101-5. PubMed ID: 3150023
    [Abstract] [Full Text] [Related]

  • 6. Prospects for the prevention of bacterial meningitis with polysaccharide vaccines.
    Gotschlich EC, Austrian R, Cvjetanović B, Robbins JB.
    Bull World Health Organ; 1978 Feb 02; 56(4):509-18. PubMed ID: 31985
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?
    Stein DM, Robbins J, Miller MA, Lin FY, Schneerson R.
    Vaccine; 2006 Jan 16; 24(3):221-8. PubMed ID: 16125824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H, Mäkelä H, Käyhty H, Jousimies H, Herva E, Hällström K, Sivonen A, Renkonen OV, Pettay O, Karanko V, Ahvonen P, Sarna S.
    N Engl J Med; 1977 Sep 29; 297(13):686-91. PubMed ID: 408682
    [Abstract] [Full Text] [Related]

  • 11. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP, Struchiner CJ, Halloran ME.
    Int J Epidemiol; 1995 Oct 29; 24(5):1050-7. PubMed ID: 8557439
    [Abstract] [Full Text] [Related]

  • 12. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues.
    Finne J, Bitter-Suermann D, Goridis C, Finne U.
    J Immunol; 1987 Jun 15; 138(12):4402-7. PubMed ID: 3108388
    [Abstract] [Full Text] [Related]

  • 13. Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.
    Park IH, Lin J, Choi JE, Shin JS.
    Mol Immunol; 2014 Jun 15; 59(2):142-53. PubMed ID: 24603121
    [Abstract] [Full Text] [Related]

  • 14. Crystallization and preliminary X-ray diffraction analysis of antigen-binding fragments which are specific for antigenic conformations of sialic acid homopolymers.
    Patenaude SI, Vijay SM, Yang QL, Jennings HJ, Evans SV.
    Acta Crystallogr D Biol Crystallogr; 1998 Sep 01; 54(Pt 5):1005-7. PubMed ID: 9757121
    [Abstract] [Full Text] [Related]

  • 15. Production and immunochemical characterization of Neisseria meningitidis group B antiserum for the diagnosis of purulent meningitis.
    Alkmin MG, Shimizu SH, Landgraf IM, Gaspari EN, Melles CE.
    Braz J Med Biol Res; 1994 Jul 01; 27(7):1627-34. PubMed ID: 7874029
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.
    Raff HV, Devereux D, Shuford W, Abbott-Brown D, Maloney G.
    J Infect Dis; 1988 Jan 01; 157(1):118-26. PubMed ID: 3121759
    [Abstract] [Full Text] [Related]

  • 18. [New vaccines against group B meningococcal diseases].
    Hietalahti J, Meri S.
    Duodecim; 2015 Jan 01; 131(6):525-32. PubMed ID: 26237895
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.